两种非交叉耐药联合方案治疗晚期乳腺癌后的反应和生存情况
Response and survival in advanced breast cancer after two non-cross-resistant combinations.
作者信息
Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G
出版信息
Br Med J. 1976 Apr 3;1(6013):801-4. doi: 10.1136/bmj.1.6013.801.
Abstract
A prospective study with two cytotoxic combinations (cyclophosphamide, methotrexate, and fluorouracil (CMF), and adriamycin plus vincristine (AV)) was carried out in 110 patients with advanced breast cancer. There was no significant difference between the treatment groups in the response rate after primary treatment, the median duration of response, and the median survival. In both groups responders survived for longer than non-responders. Secondary treatment after crossover for progression or relapse resulted in response rates of 35% for AV and 20% for CMF. Toxicity was mainly represented by reversible haemosuppression. These results are comparable with those obtained with other multiple-drug regimens, and combination chemotherapy alone seems to have reached a plateau in its capacity to control disseminated breast cancer.
摘要
对110例晚期乳腺癌患者进行了一项前瞻性研究，采用两种细胞毒性联合方案（环磷酰胺、甲氨蝶呤和氟尿嘧啶（CMF），以及阿霉素加长春新碱（AV））。在主要治疗后的缓解率、中位缓解持续时间和中位生存期方面，治疗组之间没有显著差异。两组中，缓解者的生存期均长于未缓解者。进展或复发后交叉进行的二线治疗中，AV组的缓解率为35%，CMF组为20%。毒性主要表现为可逆性血液抑制。这些结果与其他多药方案所获得的结果相当，单纯联合化疗在控制播散性乳腺癌的能力方面似乎已达到平台期。
相似文献
1
Response and survival in advanced breast cancer after two non-cross-resistant combinations.两种非交叉耐药联合方案治疗晚期乳腺癌后的反应和生存情况
Br Med J. 1976 Apr 3;1(6013):801-4. doi: 10.1136/bmj.1.6013.801.
2
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.阿霉素加长春新碱与环磷酰胺、甲氨蝶呤和5-氟尿嘧啶联合用于晚期乳腺癌的比较及联合应用。
Cancer. 1975 Apr;35(4):1108-15. doi: 10.1002/1097-0142(197504)35:4<1108::aid-cncr2820350414>3.0.co;2-z.
3
Sequential combination chemotherapy in advanced breast cancer.晚期乳腺癌的序贯联合化疗
Cancer Chemother Pharmacol. 1978;1(1):35-9. doi: 10.1007/BF00253144.
4
Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
Cancer. 1982 Oct 1;50(7):1235-44. doi: 10.1002/1097-0142(19821001)50:7<1235::aid-cncr2820500703>3.0.co;2-l.
5
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.环磷酰胺、阿霉素、5-氟尿嘧啶（CAF）与环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱、泼尼松（CMFVP）治疗转移性乳腺癌患者的比较：一项东南癌症研究组项目
Cancer. 1977 Aug;40(2):625-32. doi: 10.1002/1097-0142(197708)40:2<625::aid-cncr2820400206>3.0.co;2-m.
6
[Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].[细胞抑制疗法治疗转移性乳腺癌的鼓舞人心的结果（作者译）]
Wien Klin Wochenschr. 1981 Mar 20;93(6):205-7.
7
Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
Eur J Cancer (1965). 1980;Suppl 1:141-6.
8
Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association.长春新碱、多柔比星与环磷酰胺对比低剂量静脉注射环磷酰胺、甲氨蝶呤和5-氟尿嘧啶治疗晚期乳腺癌：皮埃蒙特肿瘤协会的一项随机试验
Cancer. 1982 Dec 1;50(11):2269-74. doi: 10.1002/1097-0142(19821201)50:11<2269::aid-cncr2820501107>3.0.co;2-l.
9
Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.晚期乳腺癌的联合化疗：两种含阿霉素的治疗方案。
Cancer. 1978 Jul;42(1):27-33. doi: 10.1002/1097-0142(197807)42:1<27::aid-cncr2820420105>3.0.co;2-3.
10
Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.晚期乳腺癌患者的联合化疗与阿霉素治疗。西南肿瘤学组研究。
Cancer. 1976 Jul;38(1):13-20. doi: 10.1002/1097-0142(197607)38:1<13::aid-cncr2820380104>3.0.co;2-5.
引用本文的文献
1
Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?杂交药物——克服抗癌药物耐药性的一种策略？
Molecules. 2021 Apr 29;26(9):2601. doi: 10.3390/molecules26092601.
2
Antitumour antibiotic containing regimens for metastatic breast cancer.用于转移性乳腺癌的含抗肿瘤抗生素方案。
Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD003367. doi: 10.1002/14651858.CD003367.pub2.
3
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.用去甲长春花碱和丝裂霉素C对晚期乳腺癌进行有效的二线化疗。
Breast Cancer Res Treat. 1993;26(1):49-53. doi: 10.1007/BF00682699.
4
Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.
Cancer Chemother Pharmacol. 1982;7(2-3):227-9. doi: 10.1007/BF00254556.
5
Multimodal treatment in operable breast cancer: five-year results of the CMF programme.可手术乳腺癌的多模式治疗：CMF方案的五年结果
Br Med J (Clin Res Ed). 1981 May 2;282(6274):1427-31. doi: 10.1136/bmj.282.6274.1427.
6
Chemotherapy of breast cancer.乳腺癌的化疗
Med Oncol Tumor Pharmacother. 1984;1(3):169-92. doi: 10.1007/BF02934139.
7
Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
Cancer Chemother Pharmacol. 1983;11(2):130-3. doi: 10.1007/BF00254262.
8
Chemotherapy of human breast-carcinoma xenografts.人乳腺癌异种移植瘤的化疗
Br J Cancer. 1980 Oct;42(4):530-6. doi: 10.1038/bjc.1980.276.
9
Update on cancer chemotherapy: general considerations and breast cancer. Part II.癌症化疗最新进展：一般考量与乳腺癌。第二部分。
J Natl Med Assoc. 1985 Sep;77(9):691-703.
10
The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer.
Cancer Chemother Pharmacol. 1985;15(3):278-82. doi: 10.1007/BF00263901.
本文引用的文献
1
Ranking procedures for arbitrarily restricted observation.任意受限观察的排序程序。
Biometrics. 1967 Mar;23(1):65-78.
2
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
Cancer. 1975 Jul;36(1):90-7. doi: 10.1002/1097-0142(197507)36:1<90::aid-cncr2820360104>3.0.co;2-h.
3
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.阿霉素加长春新碱与环磷酰胺、甲氨蝶呤和5-氟尿嘧啶联合用于晚期乳腺癌的比较及联合应用。
Cancer. 1975 Apr;35(4):1108-15. doi: 10.1002/1097-0142(197504)35:4<1108::aid-cncr2820350414>3.0.co;2-z.
Zotero 插件